Asset Details
Do you wish to reserve the book?
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Do you wish to request the book?
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
2013
Overview
In two studies of sofosbuvir for previously untreated HCV infection, patients with genotype 1, 4, 5, or 6 had a 90% rate of sustained virologic response in a single-group study. In a study of sofosbuvir–ribavirin versus peginterferon–ribavirin for patients with genotype 2 or 3, the response rate was 67% in each group.
As many as 170 million persons are chronically infected with the hepatitis C virus (HCV) worldwide, and more than 350,000 die annually from liver disease caused by HCV.
1
,
2
Estimates of the number of persons in the United States who have chronic HCV infection range from 2.7 million to 5.2 million.
3
,
4
For previously untreated cases of HCV genotype 1 infection (representing more than 70% of all cases of chronic HCV infection in the United States), the current standard of care is 12 to 32 weeks of an oral protease inhibitor combined with 24 to 48 weeks of peginterferon alfa-2a . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ Fatigue
/ Female
/ Genotype
/ Headache
/ Hepatitis C, Chronic - drug therapy
/ Hepatitis C, Chronic - virology
/ Humans
/ Interferon-alpha - adverse effects
/ Interferon-alpha - therapeutic use
/ Male
/ Nausea
/ Polyethylene Glycols - adverse effects
/ Polyethylene Glycols - therapeutic use
/ Recombinant Proteins - adverse effects
/ Recombinant Proteins - therapeutic use
/ Uridine Monophosphate - adverse effects
/ Uridine Monophosphate - analogs & derivatives
